Copyright
©The Author(s) 2020.
World J Clin Oncol. Feb 24, 2020; 11(2): 53-73
Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.53
Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.53
Table 1 The World Health Organization, Response Evaluation Criteria in Solid Tumors version 1.0 and Response Evaluation Criteria in Solid Tumors version 1.1 criteria1
WHO | RECIST v1.0 | RECIST v1.1 | |
Method | Sum of products of two longest diameters in perpendicular dimensions (bidimensional; surface area) | Sum of longest diameters of target lesions (unidimensional) | Sum of longest diameters of non-nodal target lesions and short axis of nodal target lesions (unidimensional) |
No. of measured lesion | All lesions | Target lesions: maximum 5 per organ, 10 in total | Target lesions: Maximum 2 per organ, 5 in total |
Response | |||
CR | Disappearance of all known disease, confirmed at 4 wk2 | Disappearance of all known disease, confirmed at 4 wk | Disappearance of all known disease, confirmed at 4 wk, lymph nodes must be < 10 mm short axis |
PR | ≥ 50% decrease from baseline, confirmed at 4 wk | ≥ 30% decrease from baseline, confirmed at 4 wk | ≥ 30% decrease from baseline, confirmed at 4 wk |
SD | Neither PR nor PD criteria met | Neither PR nor PD criteria met | Neither PR nor PD criteria met |
PD | ≥ 25% increase, no CR, PR, or SD, new lesion (s), ≥ 25% increase in 1 lesion | ≥ 20% increase over smallest sum observed, no CR, PR, or SD, new lesion(s) | ≥ 20% increase over smallest sum observed, no CR, PR, or SD, new lesion(s)3. The sum must also demonstrate an absolute increase of at least 5 mm |
- Citation: Aykan NF, Özatlı T. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol 2020; 11(2): 53-73
- URL: https://www.wjgnet.com/2218-4333/full/v11/i2/53.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i2.53